In response to media enquiries on the consensus interim recommendations on the use of COVID-19 vaccines in Hong Kong published by the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases under the Centre for Health Protection (CHP) of the Department of Health today (January 21), the CHP gave the following reply:
The recommendations were reached at the joint meeting by the Committees on January 7. The recommendations by the Committees focused on two vaccines, namely BNT162b2 provided by Fosun Pharma/BioNTech and AZD1222 provided by AstraZeneca, of which phase 3 clinical trial data was already available on the day of the meeting. The discussion and recommendations were based on the data and information available as of January 7. As regards the CoronaVac, vaccine provided by Sinovac Biotech (Hong Kong) Limited (Sinovac) to Hong Kong, the Committees will discuss again should more clinical information become available.
The Committees will update the recommendations in due course based on the latest situation and development.
Follow this news feed: East Asia